Erica N Evans

2.9k citations

44 papers · 1.2k indexed · h-index 19

Co-authors: Daniel G. Tenen Hanna S. Radomska Juswinder Singh William Westlin Christoph Lengauer Mariana Nacht Alexandra K. Gardino Michael P. Sheets
Topics: Mast cells and histamine (9 papers)Chronic Lymphocytic Leukemia Research (6 papers)Lung Cancer Treatments and Mutations (6 papers)
Cited by: Genetics Hematology Immunology
Journals: Nature Medicine Journal of Clinical Oncology The Journal of Cell Biology
Partner nations: United States United Kingdom Germany

In The Last Decade

Erica N Evans

43 papers receiving 1.2k citations

Peers

Countries citing papers authored by Erica N Evans

Since Specialization

Citations

This map shows the geographic impact of Erica N Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica N Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica N Evans more than expected).

Fields of papers citing papers by Erica N Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erica N Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica N Evans. The network helps show where Erica N Evans may publish in the future.

Co-authorship network of co-authors of Erica N Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Erica N Evans. A scholar is included among the top collaborators of Erica N Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erica N Evans. Erica N Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Use of the microfluidic impedance red cell assay in sickle cell disease 2025 ·Blood Advances ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Jon Wade,Erica N Evans,Michael A. Suster,Pedram Mohseni,Umut A. Gürkan,Vivien Sheehan	0
2	PU.1-c-Jun interaction is crucial for PU.1 function in myeloid development 2022 ·Communications Biology ·(unknown),Boris Bartholdy,Yukiya Yamamoto,Erica N Evans,Meritxell Alberich-Jordà,Philipp B. Staber,Touati Benoukraf,Pu Zhang,Junyan Zhang,(unknown),John D. Crispino,Trang Hoang,Mahmoud A. Bassal,Daniel G. Tenen	21
3	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial 2021 ·Nature Medicine ·Daniel J. DeAngelo,Deepti Radia,Tracy I. George,William A. Robinson,Albert Quiery,Mark W. Drummond,Prithviraj Bose,Elizabeth O. Hexner,Elliott F. Winton,Hans‐Peter Horny,Meera Tugnait,Oleg Schmidt-Kittler,Erica N Evans,Huimin Lin,Brenton G. Mar,Srđan Verstovšek,Michael W. Deininger,Jason Gotlib	88
4	P2.03-44 BLU-667 Demonstrates Robust Activity in RET Fusion-Driven Intracranial Tumor Models 2019 ·Journal of Thoracic Oncology ·Erica N Evans,Wei Hu,(unknown),Klaus P. Hoeflich,Marion Dorsch	14
5	Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis 2019 ·Leukemia ·Johannes Lübke,Nicole Naumann,(unknown),Juliana Schwaab,Georgia Metzgeroth,Erica N Evans,Alexandra K. Gardino,Christoph Lengauer,Wolf‐Karsten Hofmann,Alice Fabarius,Nicholas C.P. Cross,Andreas Reiter,Mohamad Jawhar	33
6	An innovative medical student curriculum to address Human Papillomavirus vaccine hesitancy 2019 ·PEDIATRICS ·(unknown),Britt Erickson,Erica N Evans,Caleb Vogt,(unknown),Thomas Schmidt,Katelyn Tessier	1
7	Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors 2018 ·Clinical Cancer Research ·Yemarshet K. Gebreyohannes,Agnieszka Woźniak,(unknown),Jasmien Wellens,Jasmien Cornillie,Ulla Vanleeuw,Erica N Evans,Alexandra K. Gardino,Christoph Lengauer,Maria Dêbiec‐Rychter,Raf Sciot,Patrick Schöffski	57
8	MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement 2018 ·Journal of Thoracic Oncology ·Zofia Piotrowska,Hideko Isozaki,Jochen K. Lennerz,Subba R. Digumarthy,Justin F. Gainor,Nicolas Marcoux,Mandeep K. Banwait,Dora Dias‐Santagata,A. John Iafrate,Mari Mino–Kenudson,Rebecca J. Nagy,Richard B. Lanman,Erica N Evans,Corinne Clifford,Beni B. Wolf,Aaron N. Hata,Lecia V. Sequist	1
9	Development and Content Validity of the Advanced Systemic Mastocytosis Symptom Assessment Form (ADVSM-SAF) 2016 ·Value in Health ·(unknown),Erica N Evans,Fiona Taylor,(unknown),(unknown),(unknown),H.‐P. Horny,Andreas Reiter,Jason Gotlib,Alan L. Shields	2
10	Inhibitory Effects of Midostaurin and Blu-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis 2016 ·Blood ·Mohamad Jawhar,Nicole Naumann,(unknown),Juliana Schwaab,Georgia Metzgeroth,Erica N Evans,Alexandra K. Gardino,Christoph Lengauer,Wolf‐Karsten Hofmann,Nicholas C.P. Cross,Alice Fabarius,Andreas Reiter	2
11	A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity 2014 ·Leukemia ·Homare Eda,Loredana Santo,Diana Cirstea,Andrew J. Yee,(unknown),Neeharika Nemani,Yuko Mishima,Peter Waterman,Shirin Arastu‐Kapur,Erica N Evans,Juswinder Singh,Christopher J. Kirk,William Westlin,Noopur Raje	37
12	Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans 2013 ·Journal of Pharmacology and Experimental Therapeutics ·Erica N Evans,Richland Tester,(unknown),Russell Karp,Michael P. Sheets,Matthew Labenski,Steven R. Witowski,Heather Lounsbury,Prasoon Chaturvedi,Hormoz Mazdiyasni,Zhendong Zhu,Mariana Nacht,Martin I. Freed,Russell C. Petter,(unknown),Juswinder Singh,William Westlin	171
13	Interleukin 2-inducible T cell kinase (ITK) facilitates efficient egress of HIV-1 by coordinating Gag distribution and actin organization 2012 ·Virology ·Gillian M. Schiralli Lester,Hisashi Akiyama,Erica N Evans,Juswinder Singh,Suryaram Gummuluru,Andrew J. Henderson	11
14	Abstract 1745: Translational medicine enables rapid early clinical development of AVL-292, a highly selective, orally available inhibitor of Bruton's tyrosine kinase, in a phase 1b clinical trial 2012 ·Cancer Research ·William Westlin,(unknown),Heather Lounsbury,(unknown),Bruce A. Silver,Martin I. Freed,Daruka Mahadevan,Jeff P. Sharman,Wael A. Harb,Russell C. Petter,Juswinder Singh,Erica N Evans	4
15	Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies, 2011 ·Blood ·Erica N Evans,Richland Tester,(unknown),Prasoon Chaturvedi,Hormoz Mazdiyasni,Sabine Ponader,Bethany Tesar,Michael P. Sheets,Mariana Nacht,(unknown),(unknown),Heather Lounsbury,Russell C. Petter,Jennifer R. Brown,Jan A. Burger,Juswinder Singh,William Westlin	19
16	Does transforming growth factor-β1 predict for radiation-induced pneumonitis in patients treated for lung cancer? 2006 ·Cytokine ·Erica N Evans,Zafer Koçak,S. Zhou,Daniel Kahn,Hsin-I Huang,Donna Hollis,K. Light,Mitchell S. Anscher,L.B. Marks	35
17	Reaper-induced apoptosis in a vertebrate system 1997 ·The EMBO Journal ·Erica N Evans	71
18	Crk is required for apoptosis in Xenopus egg extracts 1997 ·The EMBO Journal ·Erica N Evans	43
19	Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient 1995 ·Journal of Infection ·Vicky Hopwood,Erica N Evans,(unknown),David W. Denning	32
20	Characterization and Chromosomal Localization of ELANH2, the Gene Encoding Human Monocyte/Neutrophil Elastase Inhibitor 1995 ·Genomics ·Erica N Evans,Jessica Cooley,Eileen Remold‐O’Donnell	21

About Erica N Evans

Erica N Evans is a scholar working on Hematology, Genetics and Immunology, having authored 44 papers that have together received 1.2k indexed citations. Recurring topics across this work include Mast cells and histamine (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Lung Cancer Treatments and Mutations (6 papers). The work is most often cited by research in Genetics (288 citations), Hematology (232 citations) and Immunology (379 citations). Erica N Evans has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Daniel G. Tenen, Hanna S. Radomska, Juswinder Singh, William Westlin, Christoph Lengauer, Mariana Nacht, Alexandra K. Gardino, Michael P. Sheets, Heather Lounsbury and Russell C. Petter. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and The Journal of Cell Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact